Neurocrine Biosciences
NBIX
#1303
Rank
A$25.60 B
Marketcap
A$252.99
Share price
2.48%
Change (1 day)
10.20%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2026 (TTM): A$10.14

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is A$10.17. In 2025 the company made an earnings per share (EPS) of A$7.04 an increase over its 2024 EPS that were of A$4.93.

EPS history for Neurocrine Biosciences from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)A$10.1444.09%
2025A$7.0442.6%
2024A$4.9333.07%
2023A$3.7157.76%
2022A$2.3569.47%
2021A$1.39-78.21%
2020A$6.36990%
2019A$0.5881.82%
2018A$0.32-113.5%
2017A-$2.380.62%
2016A-$2.3657.28%
2015A-$1.5025.61%
2014A-$1.2018.84%
2013A-$1.01-1085.71%
2012A$0.10

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
A$1.04-89.81%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
A$8.54-16.05%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
A$45.09 343.20%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
A-$0.29-102.87%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
A-$2.96-129.12%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
A$7.56-25.68%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
A-$11.02-208.32%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
A$2.23-78.06%๐Ÿ‡ฌ๐Ÿ‡ง UK